New LBM Policy Boosts Esophageal Pre-Cancer Screening

In the recent quarter, revenue saw a 17% increase, reaching $1.5 million, with test volumes meeting expectations. A key milestone achieved is the acquisition of the first Laboratory Benefit Manager (LBM) coverage policy for EsoGuard from Concert. This policy recognizes EsoGuard as medically necessary for specific patient criteria and has led to adoption by three client health plans.

While positive momentum is building with LBM engagement and VA progress, challenges persist. The anticipated Medicare draft LCD publication is delayed due to CMS backlogs. Revenue recognition is still low at 19% of billable value, largely due to collection uncertainty. Furthermore, a substantial 72% of adjudicated claims were denied, primarily for reasons like medical necessity and missing documentation.